Sep 25, 2018 Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma Learn More
Sep 17, 2018 FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma Learn More
Aug 29, 2018 Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Learn More